Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 ...

An audit by the State Comptroller's Office found the lab allegedly abused Medicaid program resources. The lab defended itself ...

According to people familiar with the matter, the list includes certain antipyretics (fever drugs), analgesics (painkillers), ...

The Onitsha Drug Market, Anambra state is yet to open for business activities more than 15 days reopening date, and after one ...

Dermatologists are increasingly prescribing minoxidil in low-dose pills to help men and women regrow hair. The practice ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its heart disease drug, setting the stage for the 23-year-old biotech's next phase of growth.

Pharmacists have called for immediate action against the rampant illegal drug market, labeling those involved as "merchants ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...